Moderna is the most effective vaccine against hospitalizations four months after the second dose

One comparative study played by the CDC, i Centers for disease control and prevention Americans, sui three vaccines licensed in the United States puts Moderna in first place among the most effective. Everyone, therefore also Pfizer-Biontech and Johnson & Johnson (which is a single-dose), still maintains high efficacy in the prevention of delta-induced severe disease. But according to the numbers contained in the latest weekly report from the federal health agency, Between March 11 and August 15, Moderna’s effectiveness against hospitalization was higher (93%) than that of Pfizer-Biontech (88%) and that of Janssen’s product (71%).

“Although these real-world data suggest some variation in vaccine protection levels, all FDA approved or cleared Covid-19 vaccines provide substantial protection against hospitalization,” the CDC stressed. The difference between the most used vaccines in the United States, Pfizer and Moderna, seems to have been noted in a decline that began four months after the second administration in the case of the first product. But what are the reasons? ‘The differences in vaccine efficacy could be due to a higher mRNA content in the Moderna vaccine, differences in the timing between doses (three weeks for Pfizer-BioNTech versus four weeks for Moderna, but in different countries of the world such as Italy these windows have often been aligned) or possible differences between the groups that received each vaccine that did not were taken into account in the analysis, ‘the team wrote.

While an FDA committee would appear to have by now taken time on the third dose for the general population, recommending it instead for the frail, the elderly and health workers (but in Israel the real numbers say that the additional dose and the booster are needed, and how), the CDC specify that “the effectiveness of the vaccine in the case of Pfizer serum was 91% at 14-120 days from the booster but it decreased significantly 77% beyond 120 days “. A single dose of Janssen’s viral vector vaccine, on the other hand, has a comparatively lower anti-Sars-CoV-2 antibody response, as well as the protection it offers against hospitalizations ». According to the CDC, understanding the differences in the effectiveness of different products can guide individual choices and policy recommendations regarding vaccine boosters.

The study analyzed 3,689 people in 21 hospitals in 18 American states in addition to evaluating the antibody levels of 100 healthy and vaccinated volunteers. The study has limitations, because it does not include children and immunocompromised people, it focuses on hospitalizations which, however, are the essential data for the maintenance of health systems, along with obviously deaths.